Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Twelve Week, Open-label, Randomised, Parallel-group Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Oral Nintedanib in Combination With Oral Pirfenidone, Compared to Treatment With Nintedanib Alone, in Patients With Idiopathic Pulmonary Fibrosis (IPF)

NCT02579603 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT02579603
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02579603 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Twelve Week, Open-label, Randomised, Parallel-group Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Oral Nintedanib in Combination With Oral Pirfenidone, Compared to Treatment With Nintedanib Alone, in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Lead sponsor
Boehringer Ingelheim
Phase
Phase 4
Overall status
Completed
Start date
October 16, 2015
Completion date
January 31, 2017
Enrollment
105 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic pulmonary fibrosis